Search clinical trials for: Small Pox

Total 11864 results

Washington University School of Medicine

Not yet recruiting

Evaluating the Human Immune Response to the JYNNEOS Vaccine

Virus Diseases | Vaccinia

United States
ModernaTX, Inc.

Recruiting

A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

Smallpox | Mpox

United Kingdom
Institute of Tropical Medicine, Belgium

Recruiting

Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk (POQS-FU PLUS)

Monkeypox

Belgium
McMaster University

Not yet recruiting

Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT (SMART)

Monkeypox

Nigeria, Congo, The Democratic Republic of the, Uganda
National Institute of Allergy and Infectious Diseases...
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique...

Recruiting

Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC

Monkeypox

Congo, The Democratic Republic of the
Womack Army Medical Center
United States Naval Medical Center, San Diego; C.R.Darnall Army Medical Center

Not yet recruiting

Assessment of Myocarditis After Replication-Deficient Smallpox Immunization (PAMARDSI)

Myopericarditis | Small Pox
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

Monkeypox

United States, Puerto Rico
Emergent BioSolutions

Completed

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)

Smallpox

United States
Centers for Disease Control and Prevention
Bavarian Nordic; Kinshasa School of Public Health; Ministry of Public Health,...

Active, not recruiting

JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo

Monkeypox Virus Infection

Congo, The Democratic Republic of the
Emergent BioSolutions

Completed

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

Smallpox

United States
Emergent BioSolutions

Completed

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Smallpox

United States
Emergent BioSolutions

Completed

VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV

Smallpox Vaccine Adverse Reaction

Canada
Emergent BioSolutions

Completed

Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

Smallpox

United States
Emergent BioSolutions
Centers for Disease Control and Prevention

Completed

VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

Smallpox Vaccine Adverse Reaction

United States
Emergent BioSolutions

Completed

Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Smallpox

United States
Emergent BioSolutions

Completed

Safety Surveillance Study of ACAM2000® Vaccinia Vaccine

Smallpox

United States
Emergent BioSolutions
Centers for Disease Control and Prevention

Enrolling by invitation

VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection

Complication of Smallpox Vaccination
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine

Monkeypox

United States
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Follow-up of People at Risk of Monkeypox Infection: a Prospective Cohort Study (MonkeyVax)

Monkey Pox | Monkey Diseases

France
Federal Budgetary Research Institution State Research...

Completed

Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
SIGA Technologies
United States Department of Defense

Completed

Study to Assess the Safety and Pharmacokinetics of TPOXX® When Administered Orally for 28 Days

Smallpox

United States
SIGA Technologies
United States Department of Defense

Completed

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day

Smallpox

United States
SIGA Technologies
PPD; Biomedical Advanced Research and Development Authority

Completed

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

Smallpox

United States
Federal Budgetary Research Institution State Research...

Completed

Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
Federal Budgetary Research Institution State Research...

Completed

Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
SIGA Technologies
Biomedical Advanced Research and Development Authority

Withdrawn

A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox

Smallpox

United States
U.S. Army Medical Research and Development Command

Available

Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure

Smallpox | Monkeypox
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection

Communicable Diseases | Healthy
National Institute of Allergy and Infectious Diseases...

Completed

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

HIV Infections

United States
Bavarian Nordic
Biomedical Advanced Research and Development Authority

Completed

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

Smallpox

United States
Bavarian Nordic

Completed

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

Smallpox

United States
SIGA Technologies
PPD; Biomedical Advanced Research and Development Authority

Completed

Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG

Smallpox

United States
Bavarian Nordic

Completed

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Smallpox

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses to Smallpox Vaccination

Smallpox Vaccine

United States
Bavarian Nordic
US Army Medical Research Institute of Infectious Diseases

Completed

A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®

18-42 Year Old Healthy Vaccinia-naïve Subjects

Korea, Republic of
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

Smallpox

Germany
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects

Smallpox

Germany
Bavarian Nordic

Completed

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Smallpox

United States
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

Smallpox

Switzerland
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

Dermatitis, Atopic | Hay Fever

Germany
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

Atopic Dermatitis

United States, Mexico
Bavarian Nordic

Completed

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Smallpox

United States
Bavarian Nordic
National Institutes of Health (NIH)

Completed

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study

Influenza | Smallpox | Ebola | Severe Acute Respiratory Distress Syndrome | Unknown Respiratory Viruses

United States
SIGA Technologies
Biomedical Advanced Research and Development Authority

Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat (SIGA246-008)

Smallpox

United States
National Eye Institute (NEI)

Completed

Evaluation and Treatment of Eye Complications of Vaccinia Vaccination

Vaccinia

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

SIGA-246 to Treat Smallpox

Vaccinia

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

Smallpox

United States

Search clinical trials for: Small Pox

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations